Is targeted protein degradation ready to compete with established cancer therapies? The latest Phase 3 data suggest the answer may be yes. Results from the SUCCESSOR-2 trial have put mezigdomide in the spotlight. Article link 👇 #MultipleMyeloma #Oncology #ClinicalTrials

Show Post

Thank you, Angela!😊

Show Post

(3/3) Since then, the group has expanded and evolved, but Max has played a crucial role in shaping daily lab life and research activities. It has truly been a privilege to be part of your #PhDjourney, Max. I could not have imagined a better student to start my group.🥹

Show Post

(2/3) A big thank you to the entire committee & reviewers — Arne Lützen, Thomas Bredow, Gregor Hagelücken, and @medbioinorgchem.bsky.social. This holds special meaning for me because Max was the first student to join our newly established junior research group at @unibonn.bsky.social.

Show Post

(1/3) 🤩Huge congratulations to Dr Maximilian Notheis 🎓, #PhD #2 from the #KrbekGroup!🥳🎉 He was working on cyclic photoswitches and non-equilibrium states in metallo-supramolecular assemblies. Wishing you all the very best in your future endeavours! #ProudPI #SupramolecularChemistry

Show Post